help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Trotter, A.
Right arrow Articles by Pohlandt, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Trotter, A.
Right arrow Articles by Pohlandt, F.
The Journal of Clinical Endocrinology & Metabolism Vol. 84, No. 12 4531-4535
Copyright © 1999 by The Endocrine Society


Original Studies

Effects of Postnatal Estradiol and Progesterone Replacement in Extremely Preterm Infants

Andreas Trotter, Ludwig Maier, Hans-Jörg Grill, Thomas Kohn, Matthias Heckmann and Frank Pohlandt

Section of Neonatology and Pediatric Critical Care Medicine, Children’s Hospital (T.K.), Clinical Pharmacy (L.M.), and the Department of Obstetrics and Gynecology (H.-J.G.), University of Ulm, 89075 Ulm, Germany

Address all correspondence and requests for reprints to: Dr. A. Trotter, Section of Neonatology and Pediatric Critical Care Medicine, Children’s Hospital, University of Ulm, Prittwitzstrasse 43, 89075 Ulm, Germany. E-mail: andreas.trotter{at}medizin.uni-ulm.de

The fetus is supplied from the placenta with estradiol (E2) and progesterone (P) in increasing amounts during gestation. After delivery of a premature infant, placental supply is disrupted, resulting in a rapid decrease in E2 and P. Replacement of these placental hormones may restore intrauterine conditions and may be beneficial for bone mineral accretion, clinical course, and outcome. Thirty female infants with a median gestational age of 26.6 weeks (between 24.1–28.7) and a birth weight of 675 g (370–990) were randomized to receive E2 and P replacement, aiming to maintain plasma levels equaling the intrauterine levels, or no replacement. The E2 and P replacement was started iv and was followed by transepidermal administration for a total duration of 6 weeks. Repeated measurements included plasma levels of E2, P, FSH, and LH; uterine volume; calcium and phosphorus in spot urine specimens; and bone mineral accretion by single photon absorption densitometry. Further, the incidence of chronic lung disease and various clinical outcome data were recorded. The plasma levels of E2 and P were within the intrauterine range with median replacements of 2.30 mg/kg·day E2 (1.13–6.23) and 21.20 mg/kg·day P (11.23–27.36), iv. Three- and 6-fold higher doses of E2 and P were needed via the transepidermal route. The uterine volumes increased, and FSH and LH as indicators for biological effectiveness were significantly lowered with replacement. The bone mineral accretion rates tended to be higher, and the incidence of chronic lung disease tended to be lower (0% vs. 29%; P = 0.097). E2 and P replacement via iv and transepidermal routes is capable of maintaining plasma levels as high as those in utero with biological effectiveness. Trends toward improved postnatal bone mineral accretion and less chronic lung disease were found with the hormone replacement. Further and more extensive studies are warranted to address the role of this new approach in the care of extremely premature infants.




This article has been cited by other articles:


Home page
PediatricsHome page
R. F. Greaves, R. W. Hunt, A. S. Chiriano, and M. R. Zacharin
Luteinizing Hormone and Follicle-Stimulating Hormone Levels in Extreme Prematurity: Development of Reference Intervals
Pediatrics, March 1, 2008; 121(3): e574 - e580.
[Abstract] [Full Text] [PDF]


Home page
Arch. Dis. Child. Fetal Neonatal Ed.Home page
A Trotter, L Maier, M Kron, and F Pohlandt
Effect of oestradiol and progesterone replacement on bronchopulmonary dysplasia in extremely preterm infants
Arch. Dis. Child. Fetal Neonatal Ed., March 1, 2007; 92(2): F94 - F98.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
D. Massaro and G. D. Massaro
Estrogen regulates pulmonary alveolar formation, loss, and regeneration in mice
Am J Physiol Lung Cell Mol Physiol, December 1, 2004; 287(6): L1154 - L1159.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
S. Afshar, L. L. Gibson, I. S. Yuhanna, T. S. Sherman, J. D. Kerecman, P. H. Grubb, B. A. Yoder, D. C. McCurnin, and P. W. Shaul
Pulmonary NO synthase expression is attenuated in a fetal baboon model of chronic lung disease
Am J Physiol Lung Cell Mol Physiol, May 1, 2003; 284(5): L749 - L758.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Trotter, B. Bokelmann, W. Sorgo, D. Bechinger-Kornhuber, H. Heinemann, G. Schmücker, M. Oesterle, B. Köhntop, K.-H. Brisch, and F. Pohlandt
Follow-Up Examination at the Age of 15 Months of Extremely Preterm Infants after Postnatal Estradiol and Progesterone Replacement
J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 601 - 603.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1999 by The Endocrine Society